My bet is the board is now considering bringing on a real CEO to manage the company. This is based on the tone of the call last week in which management completely stated they screwed up the roll out.
We have tripled and had better than a double trading CEMP. Went back in at 10 and have been averaging down.
The vote in the efficacy was 13 positive and 0 negative. The liver issues were always known and present Because this is a life saving drug I believe this will pass and hope the stock shoots back above 20's.
There are 4 possible outcomes with 2 positive, one neutral and one negative. I think that at the least the drug will proceed with perhaps more studies. The FDA fadt tracked this because it is a life saving drug. If the drug is only approved in a narrower indication pending more studies I wouldn't expect a huge short term bump.
I am betting on a big move up, because I doubt this be completely denied and a big percentage of the stock drop is due to complete lack of confidence in management as they were very misleading while they were high fiving themselves in the glass bubble they live in.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM